5LZ4
Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
Summary for 5LZ4
Entry DOI | 10.2210/pdb5lz4/pdb |
Descriptor | Platelet-activating factor acetylhydrolase, CHLORIDE ION, 5-[2-(4,4-dimethyl-2-oxidanylidene-pyrrolidin-1-yl)ethoxy]-2-fluoranyl-benzenecarbonitrile, ... (4 entities in total) |
Functional Keywords | lp-pla2 phospholipase, hydrolase, lipid metabolism, inhibitors, lp-pla2#4 |
Biological source | Homo sapiens (Human) |
Cellular location | Secreted, extracellular space: Q13093 |
Total number of polymer chains | 1 |
Total formula weight | 44550.34 |
Authors | Woolford, A.,Day, P. (deposition date: 2016-09-29, release date: 2016-12-21, Last modification date: 2024-05-08) |
Primary citation | Woolford, A.J.,Day, P.J.,Beneton, V.,Berdini, V.,Coyle, J.E.,Dudit, Y.,Grondin, P.,Huet, P.,Lee, L.Y.,Manas, E.S.,McMenamin, R.L.,Murray, C.W.,Page, L.W.,Patel, V.K.,Potvain, F.,Rich, S.J.,Sang, Y.,Somers, D.O.,Trottet, L.,Wan, Z.,Zhang, X. Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2). J. Med. Chem., 59:10738-10749, 2016 Cited by PubMed: 27933945DOI: 10.1021/acs.jmedchem.6b01427 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.07 Å) |
Structure validation
Download full validation report![Download](/newweb/media/icons/dl.png)
![Download](/newweb/media/icons/dl.png)